有和没有钠-葡萄糖共转运蛋白 2 抑制剂的糖尿病患者的使用情况与白内障风险：真实世界观察性研究。
Diabetic patients with and without sodium-glucose cotransporter-2 inhibitors use and cataract risk: real-world observational investigation.
机构信息
School of Medicine, College of Medicine, China Medical University, Taichung, 40402, Taiwan.
Division of Cardiovascular Medicine, Department of Medicine, China Medical University Hospital, Taichung, 40447, Taiwan.
出版信息
Acta Diabetol. 2023 Jul;60(7):981-987. doi: 10.1007/s00592-023-02087-y. Epub 2023 Apr 21.
PURPOSE
We tried to define the association of type 2 diabetes mellitus (T2DM) patients with and without sodium-glucose cotransporter-2 inhibitors (SGLT2I) use and incident cataract using nationwide data in Taiwan.
METHODS
In a Cox proportional hazards regression model, we estimated the hazard ratios (HR) and 95% confidence intervals (95% CI). We considered risk factors for variables of sex, age, comorbidities and medications that we adjusted in multivariable Cox model.
RESULTS
We identified 20,768 T2DM patients in this study; 10,384 patients in the SGLT2I cohort, and 10,384 controls in the non-SGLT2I cohort. Compared with the T2DM patients without SGLT2I, T2DM patients using SGLT2I had a 2.04-fold increased risk of cataract, after adjustment by sex, age, comorbidities and medications.
CONCLUSION
Increased risk of cataract among diabetic patients who took SGLT2I was found in this study.
目的
我们试图利用台湾的全国性数据，定义使用和不使用钠-葡萄糖共转运蛋白 2 抑制剂（SGLT2I）的 2 型糖尿病（T2DM）患者与白内障发病的相关性。
方法
在 Cox 比例风险回归模型中，我们估计了风险比（HR）和 95%置信区间（95%CI）。我们考虑了性别、年龄、合并症和药物等变量的风险因素，并在多变量 Cox 模型中进行了调整。
结果
本研究共纳入 20768 例 T2DM 患者；SGLT2I 组 10384 例，非 SGLT2I 组 10384 例。与未使用 SGLT2I 的 T2DM 患者相比，调整性别、年龄、合并症和药物后，使用 SGLT2I 的 T2DM 患者发生白内障的风险增加了 2.04 倍。
结论
本研究发现，使用 SGLT2I 的糖尿病患者发生白内障的风险增加。
Zotero 插件